Saliva tests are generating increasing interest in Europe because they combine ease of use, non-invasiveness, and the potential for self-collection. For both consumers and those involved in the market for related products, it is important to understand where practical information ends and the regulatory framework begins. In short, a product related to saliva, analysis, or the interpretation of results is not simply a marketing tool.
Since the entry into force of Regulation (EU) 2017/746, known as the IVDR, the European Union has significantly strengthened the regulation of in vitro diagnostic devices. This framework explicitly concerns saliva samples and imposes high requirements for performance, traceability, and user information. Here are the essential points to better understand saliva tests, their European regulation, and key considerations regarding medical access.
Why saliva tests occupy a special place
Saliva offers a clear advantage: it allows for simple, quick, and non-invasive sample collection. For repeated use, this aspect improves acceptability compared to other types of samples. The ECDC also points out that self-collected saliva samples can be collected by non-professionals or by the individual themselves, provided that the instructions are clear and correctly followed.
This ease of use does not mean that all applications are equal. In the healthcare field, a saliva test remains an in vitro diagnostic tool when used to determine a health status from a biological sample. The European Commission points out that in vitro diagnostics cover a wide range of analyses, well beyond just epidemic contexts, with examples ranging from self-pregnancy tests to certain genetic or blood banking analyses.
For derivative products, this distinction is essential. A kit, a sampling system, or a product associated with saliva analysis can fall under a much more demanding regulatory framework as soon as it claims a health-related purpose. This is a key point to avoid confusion between consumer accessories, general medical devices, and genuine IVDs (Individual Diagnostic Tests).
The IVDR: the European reference framework
Today, the reference framework in the European Union is based on Regulation (EU) 2017/746, which replaced the former Directive 98/79/EC. This change is not merely cosmetic: the IVDR has tightened requirements for performance, technical documentation, post-market surveillance, and traceability. For economic operators, this means more evidence, more controls, and increased responsibility throughout the product lifecycle.
Important point: devices designed to analyze bodily fluids other than serum or plasma, such as urine or saliva, are explicitly included. Saliva tests are therefore not in a gray area. They must meet the same validation and performance standards as other IVDs, depending on their intended purpose, risk, and use.
This regulatory strengthening is also a positive signal for adult users in France and Europe. A stricter framework aims to improve the reliability of products placed on the market, regulate marketing claims, and limit misleading practices. CE marking remains central, but it is part of a much broader set of technical and clinical requirements.
CE marking, performance and controls: what you really need to understand
CE marking is often seen as a reassuring shortcut. In practice, however, it does not replace the performance evaluation required by the IVDR. A saliva test does not become credible simply because a logo appears on the packaging: it must demonstrate its analytical and clinical performance according to the requirements applicable to its category.
For certain higher-risk devices, the involvement of notified bodies is required. Depending on the circumstances, European Union Reference Laboratories may also be involved. The Commission is continuing to deploy these EU Reference Laboratories, with a call for applications published for 2026 and a guidance update dated May 12, 2026.
In other words, the regulatory environment is becoming more structured and operational. For the public, this helps to better distinguish a properly regulated product from one with vague claims. For brands and distributors of derivative products, it requires avoiding any ambiguity about the product's exact function, especially when it relates to biological analysis.
Self-testing: what the instructions absolutely must explain
When a saliva test is intended for self-testing, the IVDR requires particularly detailed user information. The instructions must describe the test procedure, including sample collection and, if necessary, preparation. They must also clearly explain how to read the result and the limitations of the device.
The regulation also requires specifying the type of user intended. This detail is far from secondary: between self-testing, near-patient testing, and use by laboratory professionals, the requirements for presentation, safety, and support are not the same. For a derivative product designed for the general public, this qualification is crucial.
Another crucial point: the instructions for a personal test must explicitly state that the user should not make any medical decisions without consulting a healthcare professional. This requirement protects against hasty interpretations, particularly in the case of a positive, negative, or inconclusive result. A test, even a simple one, can never replace medical advice on its own.
The quality of the saliva sample really changes the result
The apparent simplicity of saliva sampling should not obscure its susceptibility to practical errors. The ECDC emphasizes that improperly performed sampling can lead to false negative or inconclusive results. In other words, a good test, if misused, can become a poor indicator.
This is why instructions for self-tests must be very explicit about how to collect the sample. The timing of collection, the method used, the expected quantity, actions to avoid, and even sample storage can all influence the quality of the result. This information is not simply an addition; it is an integral part of safe use.
For consumers, this point underscores the need for caution regarding messages suggesting that saliva tests are infallible or completely automatic. For professionals in the sector, particularly those who market related products or kits, it is essential to prioritize clear, practical educational materials that comply with European regulations.
Derivatives, qualification and the boundary between MDR and IVDR
Not all saliva-related products fall under the same regulations. The European framework clearly distinguishes IVDs from general medical devices: the MDR does not apply to IVDs that fall under the IVDR category. This distinction was reiterated by the Commission in guideline MDCG 2024-11.
In practice, certain saliva-based products may be subject to specific qualification rules. The MDCG guidelines specify that certain systems incorporating saliva aspiration or collection kits must be analyzed on a case-by-case basis, depending on their intended use and how they are integrated into the diagnostic process. A simple collection component can therefore raise significant regulatory questions.
Hybrid situations also exist. When a device incorporates an IVD as an integral part, the primary qualification may fall under the MDR while still requiring compliance with the relevant IVDR requirements for the diagnostic component. For derivative products, this dual regulatory logic must be anticipated very early on to avoid positioning or communication errors.
Traceability, EUDAMED and the European market in 2026
Strengthening the framework doesn't just concern initial market access. Traceability has become much more concrete with EUDAMED. Since May 28, 2026, the UDI/Device registration module has been mandatory, improving the tracking of medical devices and IVDs within the European Union, including those based on saliva analysis.
For consumers, this development leads to a more transparent market. For manufacturers, importers, and distributors, it reinforces the need for consistency between documentation, product identity, regulatory status, and information provided. A well-traceable product is also easier to control in the event of a report, modification, or post-market surveillance.
The European framework continues to evolve, however. On December 16, 2025, the Commission proposed a targeted simplification of the rules relating to medical devices and IVDs, demonstrating that the system is still seeking a balance between safety, innovation, and market accessibility. In parallel, the ECDC maintains updated recommendations on respiratory diagnostics in 2026, which informs the discussion on the use of saliva tests in public health.
Medical access: providing accurate information without overpromising
The great advantage of saliva tests lies in their accessibility, but this accessibility must be accompanied by a good level of information. The IVDR requires that the limitations of the test, the risks of false positives and false negatives, as well as the factors that can influence the result, be clearly indicated. This transparency is essential to prevent a user from misinterpreting an indicator as a definitive diagnosis.
In the case of a self-testing product, medical access remains essential. The key message is simple: a result must be interpreted within a clinical context, especially if symptoms are present, if exposure to risk is known, or if the consequences of misinterpretation are significant. Consulting a healthcare professional is part of the proper use of the device.
For companies selling licensed products to an adult audience, the best approach is to be precise, honest, and informative. Reliable communication inspires more confidence than exaggerated promises. In an increasingly regulated European market, regulatory clarity and user information are becoming true indicators of quality.
In summary, saliva tests now benefit from a stronger, more detailed, and more operational European framework than before. The IVDR fully recognizes saliva as a valid analytical matrix, imposes robust performance requirements, and mandates better user information, particularly in the context of self-testing.
For derivative products, the best approach is to check the product's intended use, its regulatory status, the quality of its instructions, and the emphasis placed on medical advice. In an environment where compliance, traceability, and education are increasingly important, legal frameworks are not an obstacle: they are the foundation for safer, more transparent, and more credible access.
